Population
1228 patients from pivotal second-generation coronary stent trials
Design
Cohort
Follow-up
5 years
Authors
Loading...
Shifts post-stent focus to systemic atherosclerosis control beyond year 1; leaves open optimal strategies for nontarget-lesion events.
Beyond 1 year after coronary stenting, clinical outcomes are primarily driven by disease progression in non-stented segments rather than restenosis of the target lesion.
Cutlip et al. (2004) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: